|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
|
US6998116B1
(en)
|
1996-01-09 |
2006-02-14 |
Genentech, Inc. |
Apo-2 ligand
|
|
US6030945A
(en)
*
|
1996-01-09 |
2000-02-29 |
Genentech, Inc. |
Apo-2 ligand
|
|
US20050089958A1
(en)
*
|
1996-01-09 |
2005-04-28 |
Genentech, Inc. |
Apo-2 ligand
|
|
WO1997037020A1
(en)
|
1996-04-01 |
1997-10-09 |
Genentech, Inc. |
Apo-2li and apo-3 apoptosis polypeptides
|
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
|
US6462176B1
(en)
|
1996-09-23 |
2002-10-08 |
Genentech, Inc. |
Apo-3 polypeptide
|
|
US5990281A
(en)
|
1996-09-30 |
1999-11-23 |
Genentech, Inc. |
Vertebrate smoothened proteins
|
|
US6136958A
(en)
*
|
1996-09-30 |
2000-10-24 |
Genentech, Inc. |
Antibodies to vertebrate smoothened proteins
|
|
JP3394540B2
(ja)
|
1997-01-31 |
2003-04-07 |
ジェネンテク・インコーポレイテッド |
O−フコシルトランスフェラーゼ
|
|
WO1999060127A2
(en)
|
1998-05-15 |
1999-11-25 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
|
WO1998056808A1
(en)
|
1997-06-13 |
1998-12-17 |
Genentech, Inc. |
Protein recovery by chromatography followed by filtration upon a charged layer
|
|
ATE393222T1
(de)
|
1997-09-18 |
2008-05-15 |
Genentech Inc |
Dcr3 polypeptid, ein tnfr homolog
|
|
EP1967587A1
(en)
|
1997-10-10 |
2008-09-10 |
Genentech, Inc. |
APO-3 Ligand
|
|
ATE409225T1
(de)
|
1997-10-29 |
2008-10-15 |
Genentech Inc |
Durch wnt-1 induzierbare gene
|
|
ATE410512T1
(de)
|
1997-11-21 |
2008-10-15 |
Genentech Inc |
Plättchen-spezifische antigene und deren pharmazeutische verwendung
|
|
US7192589B2
(en)
|
1998-09-16 |
2007-03-20 |
Genentech, Inc. |
Treatment of inflammatory disorders with STIgMA immunoadhesins
|
|
IL136216A0
(en)
|
1997-12-03 |
2001-05-20 |
Genentech Inc |
Polypeptides and nucleic acids encoding the same
|
|
EP1947119A3
(en)
|
1997-12-12 |
2012-12-19 |
Genentech, Inc. |
Treatment of cancer with anti-erb2 antibodies in combination with a chemotherapeutic agent
|
|
PT1045906E
(pt)
|
1998-01-15 |
2009-01-27 |
Genentech Inc |
Ligando apo-2
|
|
EP1950300A3
(en)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antibody variants with higher binding affinity compared to parent antibodies
|
|
EP1484338B1
(en)
|
1998-12-22 |
2007-02-07 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
|
CA2354027A1
(en)
|
1998-12-23 |
2000-07-06 |
Genentech, Inc. |
Il-1 related polypeptides
|
|
CN1763097B
(zh)
|
1999-01-15 |
2011-04-13 |
杰南技术公司 |
具有改变的效应功能的多肽变体
|
|
DE60043367D1
(de)
|
1999-06-15 |
2009-12-31 |
Genentech Inc |
Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
|
|
NZ516830A
(en)
|
1999-06-25 |
2004-07-30 |
Genentech Inc |
Humanized anti-ErbB2 antibodies conjugated with a cytotoxic or chemotherapeutic agent for treating cancer
|
|
CA2382100A1
(en)
|
1999-08-27 |
2001-03-08 |
Genentech, Inc. |
Dosages for treatment with anti-erbb2 antibodies
|
|
CA2491610A1
(en)
|
1999-12-01 |
2001-06-07 |
Kevin P. Baker |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
EP2163625B1
(en)
|
1999-12-23 |
2014-05-21 |
Genentech, Inc. |
IL-17 and IL-17R homologous polypeptides and therapeutic uses thereof
|
|
DE60137829D1
(de)
|
2000-01-13 |
2009-04-16 |
Genentech Inc |
Menschliche stra6 polypeptide
|
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
|
EP2275549A1
(en)
|
2000-06-23 |
2011-01-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
CA2648048A1
(en)
|
2000-06-23 |
2002-01-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
|
CA2415473A1
(en)
|
2000-07-27 |
2002-02-07 |
Genentech, Inc. |
Apo-2l receptor agonist and cpt-11 synergism
|
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
|
EP2014298A3
(en)
|
2000-08-24 |
2009-10-07 |
Genentech, Inc. |
Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
|
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
|
AU1344102A
(en)
|
2000-10-12 |
2002-04-22 |
Genentech Inc |
Reduced-viscosity concentrated protein formulations
|
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
|
KR20040049829A
(ko)
|
2001-05-30 |
2004-06-12 |
제넨테크, 인크. |
다양한 질환의 치료에 유용한 항-엔지에프 항체
|
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
|
MXPA04001720A
(es)
|
2001-08-29 |
2004-05-31 |
Genentech Inc |
Acido nucleicos bv8 y polipeptidos con actividad mitogenica.
|
|
KR101008758B1
(ko)
|
2001-09-18 |
2011-01-14 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
|
WO2005049075A2
(en)
|
2003-11-17 |
2005-06-02 |
Genentech, Inc. |
Compositions and methods for the treatment of tumor of hematopoietic origin
|
|
MXPA04004671A
(es)
|
2001-11-14 |
2005-08-25 |
Johnson & Johnson |
Anticuerpos anti-interleucina-6, composiciones, metodos y usos.
|
|
JP4063769B2
(ja)
|
2001-12-28 |
2008-03-19 |
中外製薬株式会社 |
タンパク質安定化方法
|
|
MXPA04006554A
(es)
|
2002-01-02 |
2005-03-31 |
Genentech Inc |
Composiciones y metodos para diagnostico y tratamiento de tumor.
|
|
US7452675B2
(en)
|
2002-01-25 |
2008-11-18 |
The Queen's Medical Center |
Methods of screening for TRPM4b modulators
|
|
US20040258678A1
(en)
|
2002-02-22 |
2004-12-23 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
JP2005518212A
(ja)
|
2002-02-25 |
2005-06-23 |
ジェネンテック・インコーポレーテッド |
新規な1型サイトカインレセプターglm−r
|
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
|
EP2263691B1
(en)
|
2002-07-15 |
2012-08-29 |
F.Hoffmann-La Roche Ag |
Treatment of cancer with the recombinant humanized monoclonal anti-erbb2 antibody 2C4 (rhuMAb 2C4)
|
|
IL262513B
(en)
|
2002-09-11 |
2022-09-01 |
Genentech Inc |
Protein purification
|
|
EP2116551A1
(en)
|
2002-09-11 |
2009-11-11 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
EP1578364A4
(en)
|
2002-09-16 |
2011-06-08 |
Genentech Inc |
COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
|
|
WO2004028479A2
(en)
|
2002-09-25 |
2004-04-08 |
Genentech, Inc. |
Nouvelles compositions et methodes de traitement du psoriasis
|
|
CA2503330A1
(en)
|
2002-10-29 |
2004-05-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
EP1581169A4
(en)
|
2002-11-08 |
2008-09-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES RELATED TO NATURAL KILLER CELLS
|
|
JP2011516026A
(ja)
|
2002-11-26 |
2011-05-26 |
ジェネンテック・インコーポレーテッド |
免疫関連疾患の治療のための組成物と方法
|
|
CN101014364B
(zh)
|
2002-12-24 |
2012-01-18 |
里纳特神经系统学公司 |
抗ngf抗体及其使用方法
|
|
US7569364B2
(en)
|
2002-12-24 |
2009-08-04 |
Pfizer Inc. |
Anti-NGF antibodies and methods using same
|
|
KR101294959B1
(ko)
|
2003-03-12 |
2013-08-09 |
제넨테크, 인크. |
조혈을 촉진하기 위한 bv8 및(또는) eg-vegf의 용도
|
|
AU2003237792A1
(en)
|
2003-04-01 |
2004-11-23 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
|
EP1629010A1
(en)
|
2003-05-30 |
2006-03-01 |
Genentech, Inc. |
Treatment with anti-vegf antibodies
|
|
CA2528434A1
(en)
|
2003-06-05 |
2005-01-06 |
Genentech, Inc. |
Combination therapy for b cell disorders
|
|
AU2004249155B2
(en)
|
2003-06-13 |
2009-11-19 |
University Of Pittsburgh - Of The Commonwealth System Of Higher Education |
Monitoring immunologic, hematologic and inflammatory diseases
|
|
DK2784084T4
(da)
|
2003-07-08 |
2024-01-08 |
Novartis Pharma Ag |
Antagonist-antistoffer mod IL-17A/F heterologe polypeptider
|
|
HUE029951T2
(en)
|
2003-07-28 |
2017-04-28 |
Genentech Inc |
Reduction of Protein A Dissolution in Protein A Affinity Chromatography
|
|
EP1652923B1
(en)
|
2003-08-08 |
2011-10-12 |
Perseus Proteomics Inc. |
Gene overexpressed in cancer
|
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
|
WO2005060520A2
(en)
|
2003-11-25 |
2005-07-07 |
Dana-Farber Cancer Institute, Inc. |
ANTIBODIES AGAINST SARS-CoV AND METHODS OF USE THEREOF
|
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
|
AU2004298483A1
(en)
|
2003-12-11 |
2005-06-30 |
Genentech, Inc. |
Methods and compositions for inhibiting c-met dimerization and activation
|
|
CA2551097A1
(en)
|
2003-12-23 |
2005-07-14 |
Rinat Neuroscience Corp. |
Agonist anti-trkc antibodies and methods using same
|
|
DE602005018325D1
(de)
|
2004-02-19 |
2010-01-28 |
Genentech Inc |
Antikörper mit korrigierten cdr
|
|
SV2006002132A
(es)
|
2004-06-04 |
2006-04-20 |
Genentech Inc |
Uso de un anticuerpo para el tratamiento de la esclerosis multiple
|
|
KR101254815B1
(ko)
|
2004-07-20 |
2013-09-03 |
제넨테크, 인크. |
안지오포이에틴-유사 4 단백질의 저해제, 배합물, 그의용도
|
|
BRPI0513959A
(pt)
|
2004-07-30 |
2008-05-20 |
Rinat Neuroscience Corp |
anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
|
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
|
BRPI0518104B8
(pt)
|
2005-01-21 |
2021-05-25 |
Genentech Inc |
artigo industrializado e uso de anticorpo her2
|
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
|
CN105535967B
(zh)
|
2005-02-15 |
2022-05-03 |
杜克大学 |
抗cd19抗体及其在肿瘤学中的应用
|
|
EP1850874B1
(en)
|
2005-02-23 |
2013-10-16 |
Genentech, Inc. |
Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
|
|
EP1869184B1
(en)
|
2005-04-11 |
2011-09-28 |
National Research Council Of Canada |
Identification of a beta-1,3-n-acetylgalactosaminyltransferase (cgte) from campylobacter jejuni lio87
|
|
DE602006018458D1
(de)
|
2005-04-29 |
2011-01-05 |
Univ California |
Antikörper gegen histonmodifikationen für die klinische krebsdiagnose und -prognose
|
|
JO3058B1
(ar)
|
2005-04-29 |
2017-03-15 |
Applied Molecular Evolution Inc |
الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
|
|
JP5047947B2
(ja)
|
2005-05-05 |
2012-10-10 |
デューク ユニバーシティ |
自己免疫疾患のための抗cd19抗体治療
|
|
NZ563263A
(en)
|
2005-05-17 |
2010-04-30 |
Univ Connecticut |
Composition and methods for immunomodulation in an organism
|
|
HUE042561T2
(hu)
|
2005-06-30 |
2019-07-29 |
Janssen Biotech Inc |
Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
|
|
SI1919503T1
(sl)
|
2005-08-10 |
2015-02-27 |
Macrogenics, Inc. |
Identifikacija in inĺ˝eniring protiteles z variantnimi fc regijami in postopki za njih uporabo
|
|
ES2433251T5
(es)
|
2005-11-14 |
2020-03-13 |
Teva Pharmaceuticals Int Gmbh |
Anticuerpos antagonistas dirigidos contra un péptido relacionado con el gen de la calcitonina y procedimientos que utilizan los mismos
|
|
EP1979379B1
(en)
|
2005-12-02 |
2013-09-18 |
Dana-Farber Cancer Institute |
Carbonic anhydrase ix (g250) antibodies and methods of use thereof
|
|
EP3006466B1
(en)
|
2005-12-02 |
2018-08-01 |
Genentech, Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
|
WO2007120334A2
(en)
|
2005-12-15 |
2007-10-25 |
Genentech, Inc. |
Methods and compositions for targeting polyubiquitin
|
|
LT2548577T
(lt)
|
2005-12-29 |
2017-04-10 |
Janssen Biotech, Inc. |
Žmogaus anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai
|
|
RU2450020C2
(ru)
|
2006-01-05 |
2012-05-10 |
Дженентек, Инк. |
АНТИТЕЛА ПРОТИВ EphB4 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
|
DE602007011206D1
(de)
|
2006-02-06 |
2011-01-27 |
Rhode Island Hospital Providence |
Gpr30-östrogenrezeptor bei mammakarzinomen
|
|
EP1988768A2
(en)
|
2006-02-17 |
2008-11-12 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
PT1989231E
(pt)
|
2006-03-21 |
2015-09-18 |
Genentech Inc |
Terapêutica combinatória que envolve antagonistas alfa5beta1
|
|
US20100278821A1
(en)
|
2006-03-21 |
2010-11-04 |
The Regents Of The University Of California |
N-cadherin: target for cancer diagnosis and therapy
|
|
WO2007109347A2
(en)
|
2006-03-21 |
2007-09-27 |
The Regents Of The University Of California |
N-cadherin and ly6 e: targets for cancer diagnosis and therapy
|
|
JP2009531031A
(ja)
|
2006-03-23 |
2009-09-03 |
ノバルティス アーゲー |
抗−腫瘍細胞抗原抗体療法
|
|
EP2007428A2
(en)
|
2006-04-05 |
2008-12-31 |
Genentech, Inc. |
Method for using boc/cdo to modulate hedgehog signaling
|
|
US20100150928A1
(en)
|
2006-05-04 |
2010-06-17 |
Geneetech, Inc. |
Methods and compositions relating to zpa polypeptides
|
|
PL2032606T3
(pl)
|
2006-05-30 |
2014-04-30 |
Genentech Inc |
Przeciwciała i immunokoniugaty oraz ich zastosowania
|
|
EP2024391A2
(en)
|
2006-06-01 |
2009-02-18 |
Genentech, Inc. |
Crystal structure of crig and c3b: crig complex
|
|
NZ572561A
(en)
|
2006-06-07 |
2012-05-25 |
Bioalliance Cv |
Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
CN103275980B
(zh)
|
2006-07-11 |
2015-09-09 |
罗格斯新泽西州立大学 |
抗体、融合蛋白以及组合物
|
|
AU2007275654A1
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
WSX-1/p28 as a target for anti-inflammatory responses
|
|
WO2008021290A2
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
|
US8337852B2
(en)
|
2006-08-22 |
2012-12-25 |
G2 Inflammation Pty Ltd |
Anti-C5aR antibodies with improved properties
|
|
EP2061900A2
(en)
|
2006-08-25 |
2009-05-27 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
|
WO2008060776A2
(en)
|
2006-10-03 |
2008-05-22 |
University Of Medicine And Dentistry Of New Jersey |
Atap peptides, nucleic acids encoding the same and associated methods of use
|
|
CA2667019C
(en)
|
2006-10-27 |
2016-03-29 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
|
EP2097092A4
(en)
|
2006-11-21 |
2010-04-07 |
|
MODULATION OF RHAMM (CD168) FOR THE SELECTIVE DEVELOPMENT OF ADIPOSIS TISSUE
|
|
JP5391073B2
(ja)
|
2006-11-27 |
2014-01-15 |
ディアデクサス インコーポレーテッド |
Ovr110抗体組成物および使用方法
|
|
DK2140021T3
(da)
|
2007-02-22 |
2012-05-07 |
Genentech Inc |
Fremgangsmåder til detektion af inflammatorisk tarmsygdom.
|
|
JP2010520225A
(ja)
|
2007-03-02 |
2010-06-10 |
ジェネンテック, インコーポレイテッド |
低her3発現に基づくher二量化インヒビターに対する応答を予測する方法
|
|
EP2703011A3
(en)
|
2007-05-07 |
2014-03-26 |
MedImmune, LLC |
Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
|
ES2441189T3
(es)
|
2007-05-14 |
2014-02-03 |
Novimmune Sa |
Polipéptidos de unión al receptor de Fc con funciones efectoras modificadas
|
|
EP2171090B1
(en)
|
2007-06-08 |
2013-04-03 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
|
HUE025717T2
(en)
|
2007-06-08 |
2016-04-28 |
Australian Poultry Crc Pty Ltd |
Clostridium NetB toxin
|
|
HUE037633T2
(hu)
|
2007-07-09 |
2018-09-28 |
Genentech Inc |
Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
|
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
|
CA3160831A1
(en)
|
2007-07-16 |
2009-01-22 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
DK2185719T3
(en)
|
2007-08-02 |
2014-02-17 |
Novimmune Sa |
ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
AU2008308761B2
(en)
|
2007-10-02 |
2014-10-16 |
Genentech, Inc. |
NLRR-1 antagonists and uses thereof
|
|
SG10202007210RA
(en)
|
2007-11-07 |
2020-08-28 |
Genentech Inc |
Compositions and methods for treatment of microbial disorders
|
|
CN101970689A
(zh)
|
2007-11-29 |
2011-02-09 |
健泰科生物技术公司 |
炎性肠病的基因表达标志物
|
|
AR069501A1
(es)
|
2007-11-30 |
2010-01-27 |
Genentech Inc |
Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
|
|
US8883146B2
(en)
|
2007-11-30 |
2014-11-11 |
Abbvie Inc. |
Protein formulations and methods of making same
|
|
JP5840364B2
(ja)
|
2007-11-30 |
2016-01-06 |
アッヴィ バイオテクノロジー リミテッド |
タンパク質製剤及びその製造方法
|
|
CN101970483A
(zh)
|
2007-12-06 |
2011-02-09 |
达纳-法伯癌症研究公司 |
抗流感病毒抗体及其使用方法
|
|
KR101499278B1
(ko)
|
2007-12-17 |
2015-03-06 |
화이자 리미티드 |
간질성 방광염의 치료
|
|
HUE026846T2
(en)
|
2007-12-18 |
2016-08-29 |
Bioalliance Cv |
Antibodies to Recognize Carbohydrate-Containing Epitope on CD43 and CEA Expressed on Cancer Cells and Procedures for their Use
|
|
WO2009091547A1
(en)
|
2008-01-15 |
2009-07-23 |
The Board Of Trustees Of The Leland Stanford Junior University |
Markers of acute myeloid leukemia stem cells
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
|
EP3269737B1
(en)
|
2008-01-31 |
2024-06-19 |
Genentech, Inc. |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
|
CA2905334A1
(en)
|
2008-04-09 |
2009-10-15 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
|
BRPI0908665A2
(pt)
|
2008-05-16 |
2020-08-18 |
Genentech Inc |
método para a determinação da eficácia de um antagonista de integrina beta7 para o tratamento de um distúrbio inflamatório gastrointestinal, método de predição da responsividade de um paciente, método para a determinaçao da dosagem de um antagonista de integrina beta7, método para determinaçao do regime terapêutico de um antagonista de integrina beta7, método para predição de prognóstico de uma doença inflamatória intestinal, método de elaboração de um tratamento e método de identificação de uma população de linfócitos
|
|
WO2009147781A1
(ja)
|
2008-06-02 |
2009-12-10 |
国立大学法人東京大学 |
抗がん剤
|
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
|
WO2009150623A1
(en)
|
2008-06-13 |
2009-12-17 |
Pfizer Inc |
Treatment of chronic prostatitis
|
|
EP4071169A2
(en)
|
2008-08-25 |
2022-10-12 |
Dana Farber Cancer Institute, Inc. |
Conserved influenza hemagglutinin epitope and antibodies thereto
|
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
|
SG193209A1
(en)
|
2008-09-10 |
2013-09-30 |
Genentech Inc |
Methods for inhibiting ocular angiogenesis
|
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Pcsk9拮抗劑類
|
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
建南德克公司 |
治療進展型多發性硬化症之方法
|
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
|
JP5913980B2
(ja)
|
2008-10-14 |
2016-05-11 |
ジェネンテック, インコーポレイテッド |
免疫グロブリン変異体及びその用途
|
|
EP2358392B1
(en)
|
2008-11-12 |
2019-01-09 |
MedImmune, LLC |
Antibody formulation
|
|
CN102256993A
(zh)
|
2008-12-16 |
2011-11-23 |
米利波尔公司 |
蛋白的纯化
|
|
WO2010080528A1
(en)
|
2008-12-17 |
2010-07-15 |
Genentech, Inc. |
Hepatitis c virus combination therapy
|
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
|
JP2012513194A
(ja)
|
2008-12-23 |
2012-06-14 |
アストラゼネカ アクチボラグ |
α5β1に向けられた標的結合剤およびその使用
|
|
US20120009182A1
(en)
|
2008-12-23 |
2012-01-12 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
|
WO2010086828A2
(en)
|
2009-02-02 |
2010-08-05 |
Rinat Neuroscience Corporation |
Agonist anti-trkb monoclonal antibodies
|
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
|
US8410250B2
(en)
|
2009-03-25 |
2013-04-02 |
Genentech, Inc. |
Anti-FGFR3 antibodies and methods using same
|
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
|
CN102458437B
(zh)
|
2009-05-05 |
2015-06-10 |
诺维莫尼公司 |
抗il-17f抗体及其使用方法
|
|
WO2010146511A1
(en)
|
2009-06-17 |
2010-12-23 |
Pfizer Limited |
Treatment of overactive bladder
|
|
SG177580A1
(en)
|
2009-07-07 |
2012-03-29 |
Genentech Inc |
Diagnosis and treatment of autoimmune demyelinating diseases
|
|
CN102639710A
(zh)
|
2009-07-20 |
2012-08-15 |
基因泰克公司 |
克罗恩病的基因表达标记
|
|
AR077595A1
(es)
|
2009-07-27 |
2011-09-07 |
Genentech Inc |
Tratamientos de combinacion
|
|
NO2462158T3
(OSRAM)
|
2009-08-06 |
2018-06-09 |
|
|
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
|
US20110038871A1
(en)
|
2009-08-11 |
2011-02-17 |
Veena Viswanth |
Ccr2 inhibitors for treating conditions of the eye
|
|
US8512983B2
(en)
|
2009-08-11 |
2013-08-20 |
Martin Gawlitzek |
Production of proteins in glutamine-free cell culture media
|
|
US20110053223A1
(en)
|
2009-08-14 |
2011-03-03 |
Robert Bayer |
Cell culture methods to make antibodies with enhanced adcc function
|
|
CN108409829A
(zh)
|
2009-09-01 |
2018-08-17 |
弗·哈夫曼-拉罗切有限公司 |
通过改进的a蛋白洗脱增强的蛋白质纯化
|
|
JP5887270B2
(ja)
|
2009-09-02 |
2016-03-16 |
ジェネンテック, インコーポレイテッド |
突然変異体smoothenedおよびその使用方法
|
|
PL2486141T3
(pl)
|
2009-10-07 |
2018-07-31 |
Macrogenics, Inc. |
Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
|
|
EP2488640B1
(en)
|
2009-10-14 |
2018-09-26 |
Nanyang Technological University |
Antiproliferative agent
|
|
CN102648211B
(zh)
|
2009-10-22 |
2015-04-01 |
霍夫曼-拉罗奇有限公司 |
抗hepsin抗体及其使用方法
|
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
|
ES2636971T3
(es)
|
2009-11-05 |
2017-10-10 |
F. Hoffmann-La Roche Ag |
Procedimientos y composición para la secreción de polipéptidos heterógenos
|
|
EP2498817A2
(en)
|
2009-11-12 |
2012-09-19 |
F. Hoffmann-La Roche AG |
A method of promoting dendritic spine density
|
|
EP2501409A4
(en)
|
2009-11-20 |
2015-02-18 |
Univ California |
EPITHELIAL MEMBRANE PROTEIN-2 (EMP2) AND PROLIFERATIVE VITREORETINOPATHY (PVR)
|
|
WO2011066389A1
(en)
|
2009-11-24 |
2011-06-03 |
Medimmmune, Limited |
Targeted binding agents against b7-h1
|
|
RU2015132142A
(ru)
|
2009-11-30 |
2015-12-20 |
Дженентек, Инк. |
Композиции и способы для диагностики и лечения опухоли
|
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
|
CN102770158B
(zh)
|
2009-12-21 |
2016-10-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
|
ES2585350T3
(es)
|
2009-12-23 |
2016-10-05 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti Bv8 y usos de los mismos
|
|
EP2519542B1
(en)
|
2009-12-28 |
2018-10-10 |
OncoTherapy Science, Inc. |
Anti-cdh3 antibodies and uses thereof
|
|
WO2011082187A1
(en)
|
2009-12-30 |
2011-07-07 |
Genentech, Inc. |
Methods for modulating a pdgf-aa mediated biological response
|
|
US20130137584A1
(en)
|
2010-02-01 |
2013-05-30 |
The Regents Of The University Of California |
Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
|
|
EP2533810B1
(en)
|
2010-02-10 |
2016-10-12 |
ImmunoGen, Inc. |
Cd20 antibodies and uses thereof
|
|
CN102834412B
(zh)
|
2010-02-18 |
2016-01-20 |
加利福尼亚大学董事会 |
整合素αVβ8中和抗体
|
|
AU2011221226A1
(en)
|
2010-02-23 |
2012-08-16 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
|
SA114360064B1
(ar)
|
2010-02-24 |
2016-01-05 |
رينات نيوروساينس كوربوريشن |
طرق وأجسام مضادة معارضة ضد مستقبل il-7
|
|
PE20130393A1
(es)
|
2010-03-11 |
2013-04-07 |
Rinat Neuroscience Corp |
Anticuerpos con union de antigenos dependiente de ph
|
|
SI2552961T1
(en)
|
2010-03-30 |
2018-02-28 |
Janssen Biotech, Inc. |
Humanized antibodies against IL-25
|
|
PE20130460A1
(es)
|
2010-05-03 |
2013-04-26 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
|
MX2012012743A
(es)
|
2010-05-03 |
2012-11-23 |
Genentech Inc |
Composiciones y metodos utiles para reducir la viscosidad de formulaciones que contienen proteina.
|
|
WO2011146394A1
(en)
|
2010-05-17 |
2011-11-24 |
Millipore Corporation |
Stimulus responsive polymers for the purification of biomolecules
|
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
|
HRP20241463T1
(hr)
|
2010-05-25 |
2025-01-03 |
F. Hoffmann - La Roche Ag |
Metode pročišćavanja polipeptida
|
|
KR20190067277A
(ko)
|
2010-05-28 |
2019-06-14 |
제넨테크, 인크. |
락테이트 데히드로게나제 및 피루베이트 데히드로게나제 키나제의 발현의 하향조절에 의한 락테이트 수준의 감소 및 폴리펩티드 생산의 증가
|
|
CA2800531C
(en)
|
2010-06-02 |
2021-05-25 |
Dana-Farber Cancer Institute, Inc. |
Humanized monoclonal antibodies and methods of use
|
|
NZ602840A
(en)
|
2010-06-03 |
2014-11-28 |
Genentech Inc |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
|
JP6029581B2
(ja)
|
2010-06-19 |
2016-11-24 |
メモリアル スローン−ケタリング キャンサー センター |
抗gd2抗体
|
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
|
BR112013003279A2
(pt)
|
2010-08-13 |
2016-06-14 |
Genentech In |
“métodos para tratar uma doença, método para neutralizar ou bloquear a atividade de il-1ß e/ou il-18, anticorpo, usos de um anticorpo e usos de um anticorpo monoclonal”
|
|
SG10201506782XA
(en)
|
2010-08-27 |
2015-10-29 |
Stem Centrx Inc |
Notum protein modulators and methods of use
|
|
PL3556396T3
(pl)
|
2010-08-31 |
2022-09-12 |
Theraclone Sciences, Inc. |
Przeciwciała neutralizujące ludzki wirus niedoboru odporności (hiv)
|
|
WO2012031273A2
(en)
|
2010-09-03 |
2012-03-08 |
Stem Centrx, Inc. |
Novel modulators and methods of use
|
|
WO2012030512A1
(en)
|
2010-09-03 |
2012-03-08 |
Percivia Llc. |
Flow-through protein purification process
|
|
ES2588981T3
(es)
|
2010-10-05 |
2016-11-08 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
|
US9562109B2
(en)
|
2010-11-05 |
2017-02-07 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the Fc domain
|
|
EP2640831A1
(en)
|
2010-11-17 |
2013-09-25 |
Sea Lane Biotechnologies,llc. |
Influenza virus neutralizing agents that mimic the binding site of an influenza neutralizing antibody
|
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
|
AU2011338425A1
(en)
|
2010-12-08 |
2013-05-02 |
Stemcentrx, Inc. |
Novel modulators and methods of use
|
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
|
JP2014509591A
(ja)
|
2011-03-15 |
2014-04-21 |
セラクローン サイエンシーズ, インコーポレイテッド |
インフルエンザの治療および診断のための組成物および方法
|
|
MX2013011130A
(es)
|
2011-03-31 |
2013-10-30 |
Genentech Inc |
Metodos de administracion de antagonistas de integrina beta7.
|
|
CN103619881B
(zh)
|
2011-04-07 |
2017-07-28 |
安姆根有限公司 |
新的egfr结合蛋白
|
|
DK2714738T3
(en)
|
2011-05-24 |
2019-01-28 |
Zyngenia Inc |
MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS
|
|
US9156911B2
(en)
|
2011-07-18 |
2015-10-13 |
Amgen Inc. |
Apelin antigen-binding proteins and uses thereof
|
|
RU2014121884A
(ru)
|
2011-11-02 |
2015-12-10 |
Дженентек, Инк. |
Хроматография перегрузки и элюирования
|
|
EP2773671B1
(en)
|
2011-11-04 |
2021-09-15 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
|
SG11201401699WA
(en)
|
2011-11-11 |
2014-09-26 |
Rinat Neuroscience Corp |
Antibodies specific for trop-2 and their uses
|
|
AU2012356206A1
(en)
|
2011-12-22 |
2014-06-26 |
Rinat Neuroscience Corp. |
Human growth hormone receptor antagonist antibodies and methods of use thereof
|
|
WO2013093693A1
(en)
|
2011-12-22 |
2013-06-27 |
Rinat Neuroscience Corp. |
Staphylococcus aureus specific antibodies and uses thereof
|
|
US20130195851A1
(en)
|
2011-12-23 |
2013-08-01 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
|
US20140050720A1
(en)
|
2012-01-09 |
2014-02-20 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
|
EP2802601B1
(en)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
|
CN104271757B
(zh)
|
2012-02-06 |
2020-06-09 |
印希彼有限公司 |
Cd47抗体及其使用方法
|
|
CN104520324A
(zh)
|
2012-02-24 |
2015-04-15 |
施特姆森特Rx股份有限公司 |
Dll3调节剂及其使用方法
|
|
CN107868128A
(zh)
|
2012-03-29 |
2018-04-03 |
诺夫免疫股份有限公司 |
抗tlr4抗体及其用途
|
|
WO2013166500A1
(en)
|
2012-05-04 |
2013-11-07 |
Dana-Farber Cancer Institute, Inc. |
Affinity matured anti-ccr4 humanized monoclonal antibodies and methods of use
|
|
JP6351572B2
(ja)
|
2012-05-10 |
2018-07-04 |
ザイムワークス,インコーポレイテッド |
Fcドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
|
|
SG10201610356YA
(en)
|
2012-06-11 |
2017-01-27 |
Amgen Inc |
Dual receptor antagonistic antigen-binding proteins and uses thereof
|
|
US20150175979A1
(en)
|
2012-07-23 |
2015-06-25 |
La Jolla Institute For Allergy And Immunology |
Ptprs and proteoglycans in autoimmune disease
|
|
EP2900696A1
(en)
|
2012-09-25 |
2015-08-05 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
|
CN114507282B
(zh)
|
2012-10-04 |
2025-05-16 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
|
AU2013326921C1
(en)
|
2012-10-05 |
2018-01-18 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
|
EP2917237A1
(en)
|
2012-11-09 |
2015-09-16 |
Pfizer Inc. |
Platelet-derived growth factor b specific antibodies and compositions and uses thereof
|
|
CN105121467B
(zh)
|
2012-12-03 |
2019-07-05 |
诺夫免疫股份有限公司 |
抗cd47抗体及其使用方法
|
|
EA036963B1
(ru)
|
2013-02-06 |
2021-01-20 |
Инхибркс, Инк. |
Применение эпитопа cd47 для получения антитела к cd47
|
|
RU2684468C2
(ru)
|
2013-02-22 |
2019-04-09 |
ЭББВИ СТЕМСЕНТРКС ЭлЭлСи |
Новые конъюгаты антител и их применения
|
|
LT2968466T
(lt)
|
2013-03-13 |
2018-10-10 |
F. Hoffmann-La Roche Ag |
Sumažintos oksidacijos kompozicijos
|
|
NZ751452A
(en)
|
2013-03-13 |
2020-04-24 |
Genentech Inc |
Antibody formulations
|
|
PT2968467T
(pt)
|
2013-03-13 |
2020-07-28 |
Hoffmann La Roche |
Formulações de oxidação reduzida
|
|
BR112015021341B1
(pt)
|
2013-03-15 |
2023-03-28 |
Dana-Farber Cancer Institute Inc. |
Anticorpos monoclonais humanizados isolados neutralizantes de flavivírus e usos terapêuticos dos mesmos
|
|
MX2015013163A
(es)
|
2013-03-15 |
2016-04-04 |
Zyngenia Inc |
Complejos multiespecificos multivalente y monovalentes y sus usos.
|
|
CN105121628B
(zh)
|
2013-03-15 |
2020-03-24 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
|
JP6482525B2
(ja)
|
2013-03-15 |
2019-03-13 |
メモリアル スローン ケタリング キャンサー センター |
高親和性抗gd2抗体
|
|
US9447193B2
(en)
|
2013-03-24 |
2016-09-20 |
Development Center For Biotechnology |
Methods for suppressing cancer by inhibition of TMCC3
|
|
RU2015145610A
(ru)
|
2013-03-27 |
2017-05-04 |
Дженентек, Инк. |
Применение биомаркеров для оценки лечения желудочно-кишечных воспалительных расстройств антагонистами бета7 интегрина
|
|
US20160083698A1
(en)
|
2013-04-19 |
2016-03-24 |
The Regents Of The University Of California |
Lone star virus
|
|
EP2994489A2
(en)
|
2013-05-07 |
2016-03-16 |
Rinat Neuroscience Corp. |
Anti-glucagon receptor antibodies and methods of use thereof
|
|
JP6462681B2
(ja)
|
2013-07-12 |
2019-01-30 |
ジェネンテック, インコーポレイテッド |
イオン交換クロマトグラフィーのインプットの最適化の解明
|
|
BR112016000853A2
(pt)
|
2013-07-16 |
2017-12-12 |
Genentech Inc |
métodos para tratar ou retardar, reduzir ou inibir a recidiva ou a progressão do câncer e a progressão de uma doença imune-relacionada em um indivíduo, para aumentar, melhorar ou estimular uma resposta ou função imune em um indivíduo e kit
|
|
EP3022224A2
(en)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
|
CN111518199A
(zh)
|
2013-07-18 |
2020-08-11 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
|
EP3705494A3
(en)
|
2013-08-14 |
2020-12-09 |
Sachdev Sidhu |
Antibodies against frizzled proteins and methods of use thereof
|
|
BR112016004242A8
(pt)
|
2013-08-28 |
2018-06-12 |
Stemcentrx Inc |
Métodos para conjugação sítio-específica de anticorpos e composições
|
|
EP3038634A4
(en)
|
2013-08-28 |
2017-10-11 |
AbbVie Stemcentrx LLC |
Novel sez6 modulators and methods of use
|
|
AU2014312031A1
(en)
|
2013-08-29 |
2016-03-24 |
City Of Hope |
Cell penetrating conjugates and methods of use thereof
|
|
EP3626742A1
(en)
|
2013-09-27 |
2020-03-25 |
F. Hoffmann-La Roche AG |
Anti-pdl1 antibody formulations
|
|
US9493563B2
(en)
|
2013-11-04 |
2016-11-15 |
Glenmark Pharmaceuticals S.A. |
Production of T cell retargeting hetero-dimeric immunoglobulins
|
|
IL245001B2
(en)
|
2013-11-13 |
2023-05-01 |
Pfizer |
Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses
|
|
EP3077412B1
(en)
|
2013-12-02 |
2023-01-04 |
Baylor College of Medicine |
Identification of a new polypeptide hormone for maintenance of optimal body weight and blood glucose
|
|
WO2015087187A1
(en)
|
2013-12-10 |
2015-06-18 |
Rinat Neuroscience Corp. |
Anti-sclerostin antibodies
|
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
|
LT3083686T
(lt)
|
2013-12-17 |
2020-01-10 |
F. Hoffmann-La Roche Ag |
Vėžinių ligų gydymo būdai naudojant pd-1 ašies rišimosi antagonistus ir taksanus
|
|
EP3083687A2
(en)
|
2013-12-17 |
2016-10-26 |
F. Hoffmann-La Roche AG |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
CN119775416A
(zh)
|
2013-12-24 |
2025-04-08 |
杨森制药公司 |
抗vista抗体及片段
|
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
US9982041B2
(en)
|
2014-01-16 |
2018-05-29 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
|
WO2015109212A1
(en)
|
2014-01-17 |
2015-07-23 |
Pfizer Inc. |
Anti-il-2 antibodies and compositions and uses thereof
|
|
CA2937539A1
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
|
AU2015231164B2
(en)
|
2014-03-19 |
2020-04-09 |
Dana-Farber Cancer Institute, Inc. |
Immunogenetic restriction on elicitation of antibodies
|
|
CN111973740A
(zh)
|
2014-03-21 |
2020-11-24 |
泰华制药国际有限公司 |
针对降钙素基因相关肽的拮抗剂抗体及其使用方法
|
|
CN106102767B
(zh)
|
2014-03-27 |
2021-08-10 |
豪夫迈·罗氏有限公司 |
用于诊断和治疗炎症性肠病的方法
|
|
WO2015161267A2
(en)
|
2014-04-18 |
2015-10-22 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to cd99
|
|
KR102366644B1
(ko)
|
2014-05-30 |
2022-02-22 |
상하이 헨리우스 바이오테크, 인크. |
항-표피 성장 인자 수용체 (egfr) 항체
|
|
DK3157561T3
(da)
|
2014-06-17 |
2020-03-23 |
Medimmune Ltd |
Forbedrede alpha-v beta-8 antistoffer
|
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
|
AU2015327781A1
(en)
|
2014-10-03 |
2017-04-20 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
|
|
AU2015328273B2
(en)
|
2014-10-06 |
2020-09-17 |
Dana-Farber Cancer Institute, Inc. |
Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
|
|
JP6770966B2
(ja)
|
2014-11-05 |
2020-10-21 |
ジェネンテック, インコーポレイテッド |
細菌における2鎖タンパク質の生成方法
|
|
BR112017009152A2
(pt)
|
2014-11-05 |
2018-03-06 |
Genentech Inc |
métodos de produção de proteínas de duas cadeias em bactérias
|
|
CN106999583A
(zh)
|
2014-11-17 |
2017-08-01 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和pd‑1轴结合拮抗剂的组合疗法
|
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
|
EP3733696A1
(en)
|
2015-01-13 |
2020-11-04 |
City of Hope |
Ctla4-binding protein peptide-linker masks
|
|
EP3795168A1
(en)
|
2015-01-16 |
2021-03-24 |
City of Hope |
Cell penetrating antibodies
|
|
TWI710571B
(zh)
|
2015-01-24 |
2020-11-21 |
中央研究院 |
腫瘤標記及其使用方法
|
|
CN107636170A
(zh)
|
2015-02-04 |
2018-01-26 |
健泰科生物技术公司 |
突变型Smoothened及其使用方法
|
|
EP3262072A1
(en)
|
2015-02-26 |
2018-01-03 |
F. Hoffmann-La Roche AG |
Integrin beta7 antagonists and methods of treating crohn's disease
|
|
CA2981504C
(en)
|
2015-03-30 |
2023-10-24 |
City Of Hope |
Mechanically interlocking complexes
|
|
JP6903587B2
(ja)
|
2015-04-03 |
2021-07-14 |
ユーリカ セラピューティックス, インコーポレイテッド |
Afpペプチド/mhc複合体を標的化する構築物およびその使用
|
|
JP6960856B2
(ja)
|
2015-04-08 |
2021-11-05 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
ヒト化インフルエンザモノクローナル抗体およびその使用方法
|
|
ES2905315T3
(es)
|
2015-04-13 |
2022-04-07 |
Pfizer |
Anticuerpos terapéuticos y sus usos
|
|
WO2016178779A1
(en)
|
2015-05-01 |
2016-11-10 |
Dana-Farber Cancer Institute, Inc. |
Methods of mediating cytokine expression with anti ccr4 antibodies
|
|
EP3294764B1
(en)
|
2015-05-15 |
2020-12-30 |
City of Hope |
Chimeric antigen receptor compositions
|
|
HRP20231392T1
(hr)
|
2015-05-15 |
2024-04-26 |
The General Hospital Corporation |
Antagonistička protutijela na superobitelj receptora za faktor tumorske nekroze
|
|
JP6884111B2
(ja)
|
2015-05-29 |
2021-06-09 |
ジェネンテック, インコーポレイテッド |
癌におけるpd−l1プロモーターのメチル化
|
|
EP3302552A1
(en)
|
2015-06-02 |
2018-04-11 |
H. Hoffnabb-La Roche Ag |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
|
KR102689256B1
(ko)
|
2015-06-17 |
2024-07-30 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 탁산을 사용하여 국소적 진행성 또는 전이성 유방암을 치료하는 방법
|
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
|
WO2017015619A1
(en)
|
2015-07-23 |
2017-01-26 |
The Regents Of The University Of California |
Antibodies to coagulation factor xia and uses thereof
|
|
US11661463B2
(en)
|
2015-08-06 |
2023-05-30 |
City Of Hope |
Cell penetrating protein-antibody conjugates and methods of use
|
|
AU2016315892B2
(en)
|
2015-09-02 |
2023-06-15 |
The Regents Of The University Of Colorado, A Body Corporate |
Compositions and methods for modulating T-cell mediated immune response
|
|
PT3359572T
(pt)
|
2015-10-06 |
2025-01-27 |
H Hoffnabb La Roche Ag |
Método para o tratamento da esclerose múltipla
|
|
KR102876923B1
(ko)
|
2015-10-23 |
2025-10-28 |
화이자 인코포레이티드 |
항-il-2 항체 및 조성물 및 이의 용도
|
|
WO2017100714A1
(en)
|
2015-12-10 |
2017-06-15 |
City Of Hope |
Cell penetrating cyanine-coupled antibodies
|
|
EP3393475B1
(en)
|
2015-12-24 |
2025-02-05 |
Corvus Pharmaceuticals, Inc. |
Ciforadent alone or in combination with atezolizumab for use in treating cancer
|
|
EP3397243A1
(en)
|
2015-12-30 |
2018-11-07 |
H. Hoffnabb-La Roche Ag |
Use of tryptophan derivatives for protein formulations
|
|
CN115400220A
(zh)
|
2015-12-30 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
|
BR112018011029A2
(pt)
|
2016-01-08 |
2018-11-21 |
Hoffmann La Roche |
métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
|
|
JP2019506398A
(ja)
|
2016-01-21 |
2019-03-07 |
ファイザー・インク |
上皮増殖因子受容体変異体iiiおよびcd3の単一および二重特異性抗体およびそれらの使用
|
|
CN109073635A
(zh)
|
2016-01-25 |
2018-12-21 |
豪夫迈·罗氏有限公司 |
用于测定t细胞依赖性双特异性抗体的方法
|
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
|
EP3413910A1
(en)
|
2016-02-12 |
2018-12-19 |
Janssen Pharmaceutica NV |
Anti-vista (b7h5) antibodies
|
|
US10870701B2
(en)
|
2016-03-15 |
2020-12-22 |
Generon (Shanghai) Corporation Ltd. |
Multispecific fab fusion proteins and use thereof
|
|
JP7468992B2
(ja)
|
2016-03-29 |
2024-04-16 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12及び/又は-23抗体の増加した間隔投与による乾癬の処置
|
|
US10836720B2
(en)
|
2016-04-01 |
2020-11-17 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 5 beta 1 and methods of use
|
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
|
SG11201809959PA
(en)
|
2016-05-10 |
2018-12-28 |
Genentech Inc |
Methods of decreasing trisulfide bonds during recombinant production of polypeptides
|
|
HUE068564T2
(hu)
|
2016-06-17 |
2025-01-28 |
Hoffmann La Roche |
Multispecifikus antitestek tisztítása
|
|
EP3487884A2
(en)
|
2016-07-22 |
2019-05-29 |
Dana Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
|
|
CN106079858B
(zh)
*
|
2016-08-03 |
2017-05-17 |
钟晴晴 |
一种丝网印刷机
|
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
HUE071741T2
(hu)
|
2016-08-15 |
2025-09-28 |
Hoffmann La Roche |
Nem-ionos felületaktív anyag mennyiségi meghatározására szolgáló kromatográfiás eljárás a nem-ionos felületaktív anyagot és polipeptidet tartalmazó összetételben
|
|
EP3507305A1
(en)
|
2016-09-02 |
2019-07-10 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
|
EP3509633A1
(en)
|
2016-09-06 |
2019-07-17 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating or preventing zika virus infection
|
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
|
KR102391338B1
(ko)
|
2016-09-16 |
2022-04-26 |
상하이 헨리우스 바이오테크, 인크. |
항-pd-1 항체
|
|
CA3037661A1
(en)
|
2016-09-23 |
2018-03-29 |
Teva Pharmaceuticals International Gmbh |
Treating cluster headache
|
|
KR20190066607A
(ko)
|
2016-09-23 |
2019-06-13 |
테바 파마슈티컬스 인터내셔널 게엠베하 |
불응성 편두통의 치료
|
|
EP3515494A4
(en)
|
2016-09-26 |
2020-10-07 |
The Brigham and Women's Hospital, Inc. |
REGULATORS OF B-LYMPHOCYTES MEDIA IMMUNOSUPPRESSION
|
|
WO2018064478A1
(en)
|
2016-09-29 |
2018-04-05 |
The Regents Of The University Of California |
NEUTRALIZING ANTIBODIES TO THE αVβ8 INTEGRIN COMPLEX FOR IMMUNOTHERAPY
|
|
MX2019003703A
(es)
|
2016-09-30 |
2020-08-13 |
Janssen Biotech Inc |
Método seguro y eficaz para tratar la psoriasis con el anticuerpo específico anti-il23.
|
|
EP3535299A1
(en)
|
2016-11-04 |
2019-09-11 |
Novimmune S.A. |
Anti-cd19 antibodies and methods of use thereof
|
|
WO2018089967A1
(en)
|
2016-11-14 |
2018-05-17 |
Virginia Commonwealth University |
Inhibitors of cancer invasion, attachment, and/or metastasis
|
|
KR20190078648A
(ko)
|
2016-11-16 |
2019-07-04 |
얀센 바이오테크 인코포레이티드 |
항-il23 특이적 항체로 건선을 치료하는 방법
|
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
CN110709419B
(zh)
|
2017-01-06 |
2023-11-28 |
博奥信生物技术(南京)有限公司 |
Erbb2抗体及其用途
|
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
|
EP3589657A1
(en)
|
2017-03-03 |
2020-01-08 |
Rinat Neuroscience Corp. |
Anti-gitr antibodies and methods of use thereof
|
|
EP3607320A4
(en)
|
2017-04-03 |
2021-04-21 |
The Regents of the University of California |
COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer
|
|
EP3609915A1
(en)
|
2017-04-12 |
2020-02-19 |
Pfizer Inc |
Antibodies having conditional affinity and methods of use thereof
|
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
|
MX420947B
(es)
|
2017-04-26 |
2025-02-10 |
Eureka Therapeutics Inc |
Constructos que reconocen específicamente glipicano 3 y usos de estos.
|
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
|
US11260117B2
(en)
|
2017-05-26 |
2022-03-01 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
|
CA3006798A1
(en)
|
2017-06-02 |
2018-12-02 |
Pfizer Inc. |
Antibodies specific for flt3 and their uses
|
|
US11827669B2
(en)
|
2017-07-19 |
2023-11-28 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
|
WO2019067015A1
(en)
|
2017-09-29 |
2019-04-04 |
City Of Hope |
RECEPTORS OF CHIMERIC ANTIGENS AND BISPECIFIC ANTIBODIES FOR THE TREATMENT OF COAT CELL LYMPHOMA
|
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
|
US20190135910A1
(en)
|
2017-11-06 |
2019-05-09 |
Janssen Biotech, Inc. |
Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody
|
|
JP2021511811A
(ja)
|
2018-02-01 |
2021-05-13 |
ファイザー・インク |
Cd70に特異的な抗体およびその使用
|
|
AU2019232624B2
(en)
|
2018-03-05 |
2025-03-06 |
Janssen Biotech, Inc. |
Methods of treating Crohn's disease with anti-IL23 specific antibody
|
|
WO2019178248A1
(en)
|
2018-03-13 |
2019-09-19 |
The Regents Of The University Of California |
Inhibitors of integrin alpha 2 beta 1 and methods of use
|
|
CN120399075A
(zh)
|
2018-03-14 |
2025-08-01 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
|
CN108357203A
(zh)
*
|
2018-04-23 |
2018-08-03 |
广州市威顿彩印有限公司 |
一种彩印产线用转叶式干燥设备及其使用方法
|
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
|
WO2019215701A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of treating depression using il-23 antibodies
|
|
SG11202010934SA
(en)
|
2018-05-23 |
2020-12-30 |
Pfizer |
Antibodies specific for gucy2c and uses thereof
|
|
WO2019224385A2
(en)
|
2018-05-24 |
2019-11-28 |
Glenmark Pharmaceuticals S.A. |
Combined bispecific antibody and immuno-oncology therapies
|
|
EP3810777A4
(en)
|
2018-06-21 |
2022-03-30 |
Yumanity Therapeutics, Inc. |
COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF NEUROLOGICAL DISORDERS
|
|
TWI819011B
(zh)
|
2018-06-23 |
2023-10-21 |
美商建南德克公司 |
以pd-1 軸結合拮抗劑、鉑劑及拓撲異構酶ii 抑制劑治療肺癌之方法
|
|
US12281151B2
(en)
|
2018-06-29 |
2025-04-22 |
City Of Hope |
CD6 targeted chimeric antigen receptors for treatment of certain autoimmune disorders
|
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
|
BR112021000673A2
(pt)
|
2018-07-18 |
2021-04-20 |
Genentech, Inc. |
métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
|
|
EP3824295A4
(en)
|
2018-07-18 |
2022-04-27 |
Janssen Biotech, Inc. |
PREDICTORS WITH DELAYED ACTION AFTER TREATMENT WITH ANTI-IL23 SPECIFIC ANTIBODIES
|
|
TW202019478A
(zh)
|
2018-08-08 |
2020-06-01 |
美商建南德克公司 |
色胺酸衍生物及l-甲硫胺酸用於蛋白質調配之用途
|
|
CN112867503A
(zh)
|
2018-08-24 |
2021-05-28 |
希望之城 |
掩蔽的细胞因子缀合物
|
|
EP3853250A4
(en)
|
2018-09-19 |
2022-06-08 |
La Jolla Institute for Immunology |
PTPRS AND PROTEOGLYCANS IN RHEUMATOID ARTHRITIS
|
|
JP7475336B2
(ja)
|
2018-09-21 |
2024-04-26 |
ジェネンテック, インコーポレイテッド |
トリプルネガティブ乳癌のための診断方法
|
|
KR20210090645A
(ko)
|
2018-11-05 |
2021-07-20 |
제넨테크, 인크. |
원핵 숙주 세포에서 2개의 사슬 단백질을 생산하는 방법
|
|
IL283192B2
(en)
|
2018-11-20 |
2025-10-01 |
Janssen Biotech Inc |
A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
|
|
BR112021019571A2
(pt)
|
2019-04-19 |
2021-12-07 |
Chugai Pharmaceutical Co Ltd |
Receptor quimérico que reconhece o sítio de modificação do anticorpo
|
|
AU2020279987A1
(en)
|
2019-05-23 |
2021-11-18 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
|
CA3142580A1
(en)
|
2019-06-03 |
2020-12-10 |
Janssen Biotech, Inc. |
Anti-tnf antibodies, compositions, and methods for the treatment of active ankylosing spondylitis
|
|
AU2020288749A1
(en)
|
2019-06-04 |
2022-02-03 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
|
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
|
JPWO2021010326A1
(OSRAM)
|
2019-07-12 |
2021-01-21 |
|
|
|
EP4004037A1
(en)
|
2019-07-26 |
2022-06-01 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
|
TWI883032B
(zh)
|
2019-08-12 |
2025-05-11 |
中國大陸商北京恩瑞尼生物科技股份有限公司 |
藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
|
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
|
EP4084808A1
(en)
|
2019-12-30 |
2022-11-09 |
City of Hope |
Methods of making and using regulatory t cells and effector t cells having chimeric antigen receptors targeted to cd6, cd19, and/or an il-13r for treatment of autoimmune disorders and cancers
|
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
|
MX2022011892A
(es)
|
2020-03-26 |
2022-10-18 |
Univ Vanderbilt |
Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2).
|
|
WO2021205325A1
(en)
|
2020-04-08 |
2021-10-14 |
Pfizer Inc. |
Anti-gucy2c antibodies and uses thereof
|
|
TW202216757A
(zh)
|
2020-04-28 |
2022-05-01 |
美國洛克菲勒大學 |
中和性抗sars-cov-2抗體及其使用方法
|
|
IL297906A
(en)
|
2020-05-05 |
2023-01-01 |
Janssen Biotech Inc |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
CN115768466A
(zh)
|
2020-05-21 |
2023-03-07 |
詹森生物科技公司 |
用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
|
|
CN115916182A
(zh)
|
2020-06-16 |
2023-04-04 |
基因泰克公司 |
用于治疗三阴性乳腺癌的方法和组合物
|
|
AU2021308574A1
(en)
|
2020-07-13 |
2023-03-09 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-IL23 specific antibody
|
|
KR20230022246A
(ko)
|
2020-07-17 |
2023-02-14 |
화이자 인코포레이티드 |
치료 항체 및 그의 용도
|
|
AR123997A1
(es)
|
2020-11-04 |
2023-02-01 |
Univ Rockefeller |
ANTICUERPOS NEUTRALIZANTES CONTRA EL SARS-CoV-2
|
|
WO2022155324A1
(en)
|
2021-01-15 |
2022-07-21 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies
|
|
EP4281479A1
(en)
|
2021-01-20 |
2023-11-29 |
Oncoresponse, Inc. |
Immunomodulatory antibodies and uses thereof
|
|
EP4305062A1
(en)
|
2021-03-12 |
2024-01-17 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
|
CA3212729A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
|
CA3212056A1
(en)
|
2021-03-22 |
2022-09-29 |
Xavier CHAUCHET |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
|
WO2022200387A1
(en)
|
2021-03-22 |
2022-09-29 |
Novimmune S.A. |
Bispecific antibodies targeting cd47 and pd-l1 and methods of use thereof
|
|
US20240218057A1
(en)
|
2021-05-06 |
2024-07-04 |
The Rockefeller University |
Neutralizing anti- sars-cov-2 antibodies and methods of use thereof
|
|
EP4408468A4
(en)
|
2021-09-28 |
2025-07-02 |
Frontaim Biomedicines Inc |
MULTIPLE FORMATS OF MOLECULAR COMPLEXES
|
|
CN118475608A
(zh)
|
2021-10-29 |
2024-08-09 |
詹森生物科技公司 |
用抗il23特异性抗体治疗克罗恩病的方法
|
|
IL312538A
(en)
|
2021-11-05 |
2024-07-01 |
Abviro Llc |
Broadly reactive human monoclonal influenza antibodies and methods for their use
|
|
EP4433501A1
(en)
|
2021-11-15 |
2024-09-25 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
|
WO2023095000A1
(en)
|
2021-11-23 |
2023-06-01 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
|
US20250333485A1
(en)
|
2022-01-27 |
2025-10-30 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
|
CN114485122A
(zh)
*
|
2022-02-24 |
2022-05-13 |
广西青松木业有限公司 |
一种隧道式木材单板烘干生产线
|
|
AU2023236386A1
(en)
|
2022-03-18 |
2024-10-10 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
|
JP2025512860A
(ja)
|
2022-03-30 |
2025-04-22 |
ヤンセン バイオテツク,インコーポレーテツド |
Il-23に特異的な抗体によって軽度から中等度の乾癬を治療する方法
|
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
|
MX2024011181A
(es)
|
2022-04-01 |
2024-09-18 |
Genentech Inc |
Derivados de hidroxipropilmetilcelulosa para estabilizar polipeptidos.
|
|
IL316289A
(en)
|
2022-04-29 |
2024-12-01 |
Purinomia Biotech Inc |
Methods and compositions for treating diseases and disorders driven by eosinophils
|
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
|
IL317070A
(en)
|
2022-05-18 |
2025-01-01 |
Janssen Biotech Inc |
Method for evaluating and treating psoriatic arthritis with IL23 antibody
|
|
WO2024084052A1
(en)
|
2022-10-21 |
2024-04-25 |
Novimmune Sa |
Pd-l1xcd28 bispecific antibodies for immune checkpoint-dependent t cell activation
|
|
WO2024097639A1
(en)
|
2022-10-31 |
2024-05-10 |
Modernatx, Inc. |
Hsa-binding antibodies and binding proteins and uses thereof
|
|
WO2024110898A1
(en)
|
2022-11-22 |
2024-05-30 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|
|
WO2024118866A1
(en)
|
2022-12-01 |
2024-06-06 |
Modernatx, Inc. |
Gpc3-specific antibodies, binding domains, and related proteins and uses thereof
|
|
WO2024173607A2
(en)
|
2023-02-14 |
2024-08-22 |
Evolveimmune Therapeutics, Inc. |
Combination of bispecific antibodies and chimeric antigen receptor t cells for treatment
|
|
WO2024206126A1
(en)
|
2023-03-27 |
2024-10-03 |
Modernatx, Inc. |
Cd16-binding antibodies and uses thereof
|
|
WO2025059037A1
(en)
|
2023-09-11 |
2025-03-20 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting b7-h4 and cd3 and methods of use thereof
|
|
CN117190671B
(zh)
*
|
2023-09-13 |
2025-08-26 |
莱阳银通纸业有限公司 |
一种种子纸快速风干设备及方法
|
|
WO2025064885A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Multispecific antibodies that bind cd3 and cd2 and methods of use thereof
|
|
WO2025064890A1
(en)
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
|
|
US20250109187A1
(en)
|
2023-09-28 |
2025-04-03 |
Novavax, Inc. |
ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19
|
|
US20250171537A1
(en)
|
2023-11-28 |
2025-05-29 |
Novimmune Sa |
Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodies
|
|
CA3249015A1
(en)
|
2024-03-20 |
2025-10-31 |
Janssen Biotech, Inc. |
Methods of treating crohn’s disease with anti-il23 specific antibody
|
|
WO2025262604A1
(en)
|
2024-06-17 |
2025-12-26 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|